Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasm Metastasis: early-phase trial registry
10 of 42 indexed Neoplasm Metastasis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #347 of 28,707 conditions by registered trial count.
42 US clinical trials · 10 currently recruiting · #347 of 28,707 conditions by registered trial count
Neoplasm Metastasis: 42 US clinical trials tracked, 10 recruiting.
Neoplasm Metastasis is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 15 of these trials.
Enrollment posture brief
Registry condition neoplasm-metastasis
OPEN 10 | RECR 24% | LATE 9 | EARLY 28 | RANK #347 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Neoplasm Metastasis lists 10 open slots (24% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasm Metastasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasm Metastasis is recruiting below its size-band peers.
10 of 42 indexed trials (23.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neoplasm Metastasis research.
Eli Lilly and Company accounts for 15 of 42 trials (35.7%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasm Metastasis enrolment sits around 152 participants.
Median target enrolment is 152 among the 42 trials that report a genuine target (sentinel values excluded). 17 of those (40.5%) plan for fewer than 100 participants.
-
Neoplasm Metastasis research is mostly interventional.
39 interventional and 3 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
42 total, page 1 of 1
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
NCT06119581
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company
NCT07213804
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
NCT07174336
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
NCT05614739
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company
NCT07218380
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT07114601
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT07046923
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co.
NCT05176665
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Henry Ford Health System
NCT05023772
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
NCT06912087
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company
NCT05288166
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company
NCT04975308
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech
NCT00781612
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Boehringer Ingelheim
NCT04886804
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Eli Lilly and Company
NCT05169567
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics
NCT03678883
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
Merck Sharp & Dohme
NCT06460961
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
NCT05440786
Hepatic Resection for Metastatic Pancreatic Cancer
Duke University
NCT02892305
Analyses of Human Samples Collected in Clinical Trials
National Cancer Institute (NCI)
NCT00339664
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
University of Washington
NCT04281784
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Sanofi
NCT00519285
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
NCT01373164
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Cancer Institute (NCI)
NCT00001832
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
NCT02124148
Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00075166
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Eli Lilly and Company
NCT00207116
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
National Cancer Institute (NCI)
NCT00001507
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie (prior sponsor, Abbott)
NCT00649207
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Cancer Institute (NCI)
NCT00001302
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Duke University
NCT00447330
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
National Cancer Institute (NCI)
NCT00001440
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
National Cancer Institute (NCI)
NCT00001570
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
NCT00130689
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
NCT00444678
Tarceva and Capecitabine for Pancreatic Cancer
Dana-Farber Cancer Institute
NCT00125021
A Study of LY2835219 in Participants With Cancer
Eli Lilly and Company
NCT02117648
Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases
University of Rochester
NCT00904553
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
NCT00946673
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Anza Therapeutics
NCT00327652
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
University of California, San Diego
NCT01114958
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 9 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasm Metastasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasm Metastasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasm Metastasis page
42 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Neoplasm Metastasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Neoplasm Metastasis trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasm Metastasis condition card totals 42 registered trials; most-linked intervention Abemaciclib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.